Nifty
Sensex
:
:
18562.75
62504.80
50.00 (0.27%)
211.16 (0.34%)

Pharmaceuticals & Drugs - Global

Rating :
52/99

BSE: 524404 | NSE: MARKSANS

59.85
28-Nov-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 58.40
  • 62.00
  • 57.50
  • 58.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5620329
  •  3398.00
  •  65.00
  •  38.60

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,412.22
  • 11.77
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,104.25
  • 0.42%
  • 1.85

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.60%
  • 2.54%
  • 39.76%
  • FII
  • DII
  • Others
  • 4.06%
  • 0.95%
  • 4.09%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.02
  • 10.31
  • 9.54

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.07
  • 26.99
  • 6.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.93
  • 41.15
  • 16.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.84
  • 11.90
  • 10.98

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.75
  • 2.31
  • 2.36

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.61
  • 8.96
  • 7.06

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
452.56
361.20
25.29%
433.77
348.96
24.30%
418.04
330.20
26.60%
362.63
358.36
1.19%
Expenses
372.30
301.10
23.65%
360.91
271.63
32.87%
354.40
234.82
50.92%
304.83
267.31
14.04%
EBITDA
80.27
60.10
33.56%
72.86
77.34
-5.79%
63.64
95.37
-33.27%
57.80
91.06
-36.53%
EBIDTM
17.74%
16.64%
16.80%
22.16%
15.22%
28.88%
15.94%
25.41%
Other Income
14.15
8.57
65.11%
16.50
5.88
180.61%
15.34
6.01
155.24%
12.06
-3.17
-
Interest
2.54
1.50
69.33%
1.80
0.97
85.57%
5.03
2.83
77.74%
0.95
1.68
-43.45%
Depreciation
14.05
7.39
90.12%
11.12
7.47
48.86%
21.36
1.33
1,506.02%
8.56
8.58
-0.23%
PBT
77.83
59.78
30.19%
76.45
74.78
2.23%
52.60
97.22
-45.90%
60.35
77.64
-22.27%
Tax
17.71
13.49
31.28%
16.26
12.18
33.50%
22.95
17.73
29.44%
12.08
18.70
-35.40%
PAT
60.12
46.29
29.88%
60.18
62.60
-3.87%
29.65
79.50
-62.70%
48.27
58.94
-18.10%
PATM
13.28%
12.81%
13.87%
17.94%
7.09%
24.08%
13.31%
16.45%
EPS
1.52
1.13
34.51%
1.46
1.51
-3.31%
0.72
1.94
-62.89%
1.18
1.44
-18.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
1,667.00
1,490.84
1,376.18
1,134.21
1,000.07
912.69
767.16
893.33
796.69
630.00
438.42
Net Sales Growth
19.18%
8.33%
21.33%
13.41%
9.57%
18.97%
-14.12%
12.13%
26.46%
43.70%
 
Cost Of Goods Sold
817.16
716.81
595.05
567.83
498.01
523.13
458.74
509.69
445.44
367.93
252.86
Gross Profit
849.84
774.02
781.13
566.38
502.07
389.57
308.42
383.63
351.25
262.07
185.56
GP Margin
50.98%
51.92%
56.76%
49.94%
50.20%
42.68%
40.20%
42.94%
44.09%
41.60%
42.32%
Total Expenditure
1,392.44
1,231.96
1,036.58
941.96
867.92
834.31
734.24
760.91
620.86
516.04
369.02
Power & Fuel Cost
-
18.59
16.42
14.38
14.34
11.83
13.27
12.58
9.72
7.80
6.12
% Of Sales
-
1.25%
1.19%
1.27%
1.43%
1.30%
1.73%
1.41%
1.22%
1.24%
1.40%
Employee Cost
-
220.30
197.32
168.42
159.07
147.75
149.70
122.42
72.61
66.44
55.91
% Of Sales
-
14.78%
14.34%
14.85%
15.91%
16.19%
19.51%
13.70%
9.11%
10.55%
12.75%
Manufacturing Exp.
-
192.77
127.47
113.32
77.14
59.90
47.34
50.44
37.59
30.11
9.85
% Of Sales
-
12.93%
9.26%
9.99%
7.71%
6.56%
6.17%
5.65%
4.72%
4.78%
2.25%
General & Admin Exp.
-
47.41
50.67
45.52
51.03
42.51
37.52
36.01
15.35
16.13
24.93
% Of Sales
-
3.18%
3.68%
4.01%
5.10%
4.66%
4.89%
4.03%
1.93%
2.56%
5.69%
Selling & Distn. Exp.
-
31.89
33.54
32.15
68.36
49.14
27.66
29.77
34.47
27.63
22.84
% Of Sales
-
2.14%
2.44%
2.83%
6.84%
5.38%
3.61%
3.33%
4.33%
4.39%
5.21%
Miscellaneous Exp.
-
4.17
16.10
0.34
-0.01
0.05
0.00
0.00
5.67
0.00
22.84
% Of Sales
-
0.28%
1.17%
0.03%
0.00%
0.01%
0%
0%
0.71%
0%
-0.80%
EBITDA
274.57
258.88
339.60
192.25
132.15
78.38
32.92
132.42
175.83
113.96
69.40
EBITDA Margin
16.47%
17.36%
24.68%
16.95%
13.21%
8.59%
4.29%
14.82%
22.07%
18.09%
15.83%
Other Income
58.05
41.85
6.69
0.33
4.62
8.47
18.85
12.72
12.23
7.28
4.40
Interest
10.32
8.45
7.99
8.75
9.66
10.22
6.78
10.16
16.05
19.13
14.60
Depreciation
55.09
44.78
36.15
26.66
22.80
26.84
30.09
28.13
16.13
15.69
15.65
PBT
267.23
247.51
302.16
157.17
104.31
49.80
14.90
106.85
155.88
86.41
43.55
Tax
69.00
60.70
63.63
36.42
23.87
14.00
3.56
24.11
43.92
12.79
-5.28
Tax Rate
25.82%
24.52%
21.06%
23.17%
22.88%
28.11%
23.89%
22.56%
28.18%
14.80%
-12.12%
PAT
198.22
184.56
235.94
117.02
76.46
32.94
8.83
78.51
109.39
71.90
45.89
PAT before Minority Interest
198.88
186.81
238.54
120.75
80.44
35.80
11.33
82.74
111.96
73.62
48.83
Minority Interest
0.66
-2.25
-2.60
-3.73
-3.98
-2.86
-2.50
-4.23
-2.57
-1.72
-2.94
PAT Margin
11.89%
12.38%
17.14%
10.32%
7.65%
3.61%
1.15%
8.79%
13.73%
11.41%
10.47%
PAT Growth
-19.86%
-21.78%
101.62%
53.05%
132.12%
273.05%
-88.75%
-28.23%
52.14%
56.68%
 
EPS
4.88
4.54
5.81
2.88
1.88
0.81
0.22
1.93
2.69
1.77
1.13

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
1,202.27
886.50
636.01
542.48
470.86
433.43
454.32
379.76
142.18
86.48
Share Capital
40.93
40.93
40.93
40.93
40.93
40.93
53.43
53.43
52.03
52.03
Total Reserves
1,068.24
845.56
595.08
501.55
429.93
392.50
400.89
326.33
90.15
34.45
Non-Current Liabilities
57.05
23.70
24.15
17.14
15.64
16.07
-1.91
1.46
22.16
10.49
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
19.82
7.88
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
1.86
2.11
1.47
1.36
1.08
0.96
0.00
0.00
0.00
0.00
Current Liabilities
356.22
298.97
228.75
232.62
234.68
296.06
259.43
286.24
319.12
297.28
Trade Payables
200.08
168.66
110.33
106.07
77.83
161.78
118.98
107.02
83.18
56.06
Other Current Liabilities
96.80
79.69
58.86
20.90
10.08
0.71
0.68
39.88
96.58
108.73
Short Term Borrowings
41.29
18.74
18.84
99.91
117.41
109.71
87.89
82.19
105.54
113.79
Short Term Provisions
18.05
31.88
40.72
5.74
29.36
23.85
51.88
57.15
33.82
18.70
Total Liabilities
1,636.24
1,228.03
902.02
802.46
730.73
751.81
720.20
675.56
490.10
401.24
Net Block
428.31
309.36
302.72
269.73
279.38
266.98
269.65
165.90
145.65
156.12
Gross Block
726.26
551.92
565.39
506.26
495.35
456.49
429.47
297.78
261.70
256.88
Accumulated Depreciation
297.96
242.56
262.67
236.54
215.97
189.52
159.82
131.89
116.05
100.76
Non Current Assets
435.04
325.20
308.45
271.02
280.19
267.92
280.06
166.72
147.15
157.32
Capital Work in Progress
2.57
11.68
0.00
0.00
0.00
0.36
0.00
0.00
0.00
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
4.16
4.16
5.73
1.29
0.82
0.59
10.41
0.83
1.50
1.20
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,201.20
902.82
593.59
531.44
450.54
483.88
440.15
508.83
342.95
243.93
Current Investments
0.44
0.26
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
424.44
404.32
241.84
293.25
218.12
190.09
167.79
130.11
102.59
77.69
Sundry Debtors
394.78
271.95
243.35
176.60
176.91
247.58
217.29
183.45
169.61
131.31
Cash & Bank
349.26
212.18
93.73
33.54
39.88
25.16
35.30
185.27
46.95
15.88
Other Current Assets
32.29
14.11
11.26
28.06
15.63
21.05
19.76
10.01
23.80
19.04
Short Term Loans & Adv.
3.06
0.00
3.40
0.00
0.00
20.96
19.76
10.01
23.80
19.04
Net Current Assets
844.98
603.85
364.83
298.82
215.86
187.82
180.71
222.60
23.83
-53.36
Total Assets
1,636.24
1,228.02
902.04
802.46
730.73
751.80
720.21
675.55
490.10
401.25

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
99.26
178.59
233.33
27.40
50.09
14.06
30.80
154.51
64.84
38.56
PBT
247.51
302.16
157.17
104.31
49.80
14.90
106.85
109.40
71.91
45.88
Adjustment
35.31
56.57
42.04
31.88
43.99
26.58
39.63
24.26
19.57
27.85
Changes in Working Capital
-110.70
-131.61
59.12
-81.79
-36.23
-6.04
-88.14
20.27
-26.01
-35.18
Cash after chg. in Working capital
172.12
227.12
258.33
54.40
57.56
35.44
58.34
153.94
65.47
38.56
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-72.86
-48.53
-25.00
-27.00
-7.46
-21.37
-27.54
-0.89
-0.27
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-41.69
-44.85
-59.58
-13.48
-38.81
-20.73
-123.01
-33.19
-4.49
-5.43
Net Fixed Assets
-24.09
-28.48
-23.87
-23.07
-5.86
-11.49
-22.01
-32.23
-2.62
-4.85
Net Investments
-0.18
-0.26
0.00
0.00
-1.78
-2.85
-163.82
0.00
0.00
-44.11
Others
-17.42
-16.11
-35.71
9.59
-31.17
-6.39
62.82
-0.96
-1.87
43.53
Cash from Financing Activity
79.51
-15.29
-113.55
-20.78
3.38
-3.47
-57.75
16.99
-29.28
-39.64
Net Cash Inflow / Outflow
137.08
118.46
60.19
-6.86
14.67
-10.14
-149.96
138.32
31.07
-6.51
Opening Cash & Equivalents
212.18
93.73
33.54
39.72
25.05
35.30
185.27
46.95
15.88
22.39
Closing Cash & Equivalent
349.26
212.18
93.73
32.85
39.72
25.16
35.30
185.27
46.95
15.88

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
27.10
21.66
15.54
13.25
11.50
10.59
10.79
8.97
3.34
1.89
ROA
13.04%
22.40%
14.17%
10.49%
4.83%
1.54%
11.86%
19.21%
16.52%
12.42%
ROE
18.72%
31.33%
20.49%
15.88%
7.92%
2.59%
20.45%
45.15%
73.02%
0.00%
ROCE
23.82%
39.76%
25.57%
18.51%
10.60%
3.99%
23.16%
44.64%
38.30%
44.72%
Fixed Asset Turnover
2.42
2.49
2.12
2.00
1.92
1.73
2.46
2.85
2.43
1.73
Receivable days
78.56
67.57
67.57
64.51
84.88
110.59
81.87
80.88
87.17
101.60
Inventory Days
97.65
84.73
86.10
93.32
81.63
85.14
60.86
53.30
52.22
62.88
Payable days
93.88
85.57
45.09
38.48
55.10
65.56
54.58
56.06
48.85
59.34
Cash Conversion Cycle
82.33
66.73
108.58
119.35
111.40
130.17
88.15
78.13
90.54
105.14
Total Debt/Equity
0.04
0.02
0.03
0.18
0.25
0.25
0.19
0.23
1.12
1.88
Interest Cover
30.31
38.84
18.97
11.80
5.87
3.20
11.52
10.72
5.52
3.98

News Update:


  • Marksans Pharma enters into Business Transfer Agreement with Tevapharm India
    11th Oct 2022, 15:42 PM

    Through the acquisition, the company plans to double the existing Indian capacity from 8bn units per annum currently

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.